NASDAQ: NERVMinerva Neurosciences Inc Stock
$2.16+0.00 (+0%)
Updated Jan 24, 2025
NERV Price
$2.16
Fair Value Price
$6.29
Market Cap
$15.11M
52 Week Low
$2.03
52 Week High
$13.49
P/E
-4.8x
P/B
-0.7x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$3.31M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.98
Operating Cash Flow
-$20M
Beta
0.85
Next Earnings
Feb 20, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NERV Overview
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NERV's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Value
C
Growth
C
Momentum
A
Sentiment
D
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NERV
Ranked#149 of 555
Ranked#149 of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.17 | A | |
| $122.04 | A | |
| $2.96 | A |
Be the first to know about important NERV news, forecast changes, insider trades & much more!
NERV News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NERV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NERV ($2.16) is undervalued by 65.65% relative to our estimate of its Fair Value price of $6.29 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NERV ($2.16) is significantly undervalued by 65.65% relative to our estimate of its Fair Value price of $6.29 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NERV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NERV due diligence checks available for Premium users.
Valuation
NERV fair value
Fair Value of NERV stock based on Discounted Cash Flow (DCF)
Price
$2.16
Fair Value
$6.29
Undervalued by
65.65%
NERV ($2.16) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NERV ($2.16) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NERV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NERV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.8x
Industry
-188.16x
Market
30.33x
NERV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.7x
Industry
5.04x
NERV's financial health
Profit margin
Revenue
$0.0
Net Income
$22.5M
Profit Margin
0%
NERV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$42.8M
Liabilities
$64.5M
Debt to equity
-2.98
NERV's short-term assets ($27.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NERV's long-term liabilities ($60.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NERV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NERV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.4M
Investing
$0.0
Financing
$0.0
NERV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NERV vs Biotech Stocks
Minerva Neurosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.